Department of Radiation Oncology, University of Florida College of Medicine, 2015 North Jefferson Street, Jacksonville, FL, 32206, USA.
Curr Treat Options Oncol. 2021 Mar 1;22(4):34. doi: 10.1007/s11864-021-00831-6.
Desmoid tumors have a variable clinical course that ranges from indolence or spontaneous regression to an aggressive pattern marked by local invasion. Up to half may remain stable or regress; watchful waiting is the preferred approach in the initial management of desmoid tumors. Symptomatic or progressive tumors or those that may affect adjacent critical structures require surgery, radiotherapy, or systemic therapy. Although radiotherapy effectively controls desmoid tumors in most cases, concerns regarding late toxicity exist. Definitive radiotherapy for macroscopic disease is indicated when a non-morbid complete surgical resection cannot be accomplished and provides similar control rates to surgery plus radiotherapy but avoids toxicity from combined-modality treatment (surgery and radiotherapy). Adjuvant radiotherapy can be considered for microscopically involved margins, particularly for recurrent cases or when a future recurrence may be challenging to treat. Large size, extremity site, and younger age are poor prognostic factors after radiotherapy. In the extremity, radiotherapy may have superior outcomes to surgery. Younger patients, especially children, are challenging to manage as they are at particular risk for late toxicity due to the number of potential years at risk. For patients under 20 years old, for whom a non-morbid complete resection is not possible, we recommend systemic therapy as the first line of treatment. Although the long-term efficacy of systemic therapy is unproven, this strategy allows additional time for growth and development prior to radiotherapy. In younger patients and those with axial desmoid tumors adjacent to critical organs, consideration should be given to using proton therapy as the dosimetric advantages may mitigate some of the toxicity associated with conventional radiotherapy.
韧带样纤维瘤的临床病程多变,从惰性或自发消退到局部侵袭的侵袭性模式不等。多达一半的患者可能保持稳定或消退;在韧带样纤维瘤的初始管理中,密切观察是首选方法。有症状或进展性肿瘤或可能影响邻近关键结构的肿瘤需要手术、放疗或全身治疗。虽然放疗在大多数情况下能有效控制韧带样纤维瘤,但存在对迟发性毒性的担忧。当不能完成非致死性完全手术切除且明确的放疗与手术加放疗具有相似的控制率但避免联合治疗(手术和放疗)的毒性时,应对宏观疾病进行确定性放疗。对于显微镜下累及的边缘,可以考虑辅助放疗,特别是在复发病例或将来的复发可能难以治疗时。放疗后,大肿瘤、肢体部位和年轻的年龄是预后不良的因素。在肢体中,放疗的结果可能优于手术。年轻患者,尤其是儿童,由于存在潜在的数年风险,因此特别容易受到迟发性毒性的影响,这给他们的管理带来了挑战。对于 20 岁以下的患者,由于不能进行非致死性的完全切除,我们建议将全身治疗作为一线治疗。尽管全身治疗的长期疗效尚未得到证实,但这种策略允许在放疗前有更多的时间进行生长和发育。对于年轻患者和那些位于邻近重要器官的轴位韧带样纤维瘤患者,应考虑使用质子治疗,因为剂量学优势可能减轻与常规放疗相关的一些毒性。